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Abstract 
Metastatic clear-cell renal cell carcinoma (ccRCC) affects thousands of patients worldwide each year. 
Antiangiogenic therapy has been shown to have beneficial effects initially, but resistance is eventually 
developed. Therefore, it is important to accurately track the response of cancer to different therapeutics in 
order to appropriately adjust the therapy to maximize efficacy. Change in tumor volume is the current gold 
standard for determining efficacy of treatment. However, functional variations can occur much earlier than 
measurable volume changes. Contrast-enhanced ultrasound (CEUS) is an important tool for assessing tumor 
progression and response to therapy, since it can monitor functional changes in the physiology. In this study, 
we demonstrate how ultrasound molecular imaging (USMI) can accurately track the evolution of the disease 
and molecular response to treatment. 
Methods A cohort of NSG (NOD/scid/gamma) mice was injected with ccRCC cells and treated with either 
the VEGF inhibitor SU (Sunitinib malate, Selleckchem, TX, USA) or the Notch pathway inhibitor GSI (Gamma 
secretase inhibitor, PF-03084014, Pfizer, New York, NY, USA), or started on SU and later switched to GSI 
(Switch group). The therapies used in the study focus on disrupting angiogenesis and proper vessel 
development. SU inhibits signaling of vascular endothelial growth factor (VEGF), which is responsible for the 
sprouting of new vasculature, and GSI inhibits the Notch pathway, which is a key factor in the correct 
maturation of newly formed vasculature. Microbubble contrast agents targeted to VEGFR-2 (VEGF Receptor) 
were delivered as a bolus, and the bound agents were imaged in 3D after the free-flowing contrast was 
cleared from the body. Additionally, the tumors were harvested at the end of the study and stained for CD31. 
Results The results show that MI can detect changes in VEGFR-2 expression in the group treated with SU 
within a week of the start of treatment, while differences in volume only become apparent after the mice have 
been treated for three weeks. Furthermore, USMI can detect response to therapy in 92% of cases after 1 
week of treatment, while the detection rate is only 40% for volume measurements. The amount of targeting 
for the GSI and Control groups was high throughout the duration of the study, while that of the SU and Switch 
groups remained low. However, the amount of targeting in the Switch group increased to levels similar to 
those of the Control group after the treatment was switched to GSI. CD31 staining indicates significantly 
lower levels of patent vasculature for the SU group compared to the Control and GSI groups. Therefore, the 
results parallel the expected physiological changes in the tumor, since GSI promotes angiogenesis through the 
VEGF pathway, while SU inhibits it.  
Conclusion This study demonstrates that MI can track disease progression and assess functional changes in 
tumors before changes in volume are apparent, and thus, CEUS can be a valuable tool for assessing response 
to therapy in disease. Future work is required to determine whether levels of VEGFR-2 targeting correlate 
with eventual survival outcomes. 
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Introduction and Background 
Metastatic clear-cell renal cell carcinoma (ccRCC) 
results in over 14,000 deaths annually in the US, and 
over 60,000 new cases are expected to be diagnosed 
this year [1]. This type of cancer is characterized by 
increased angiogenesis due to gene mutations in the 
von Hippel-Lindau gene (VHL), which upregulates 
various pro-angiogenic factors [2,3]. The most 
common type of treatment involves anti-angiogenic 
therapeutics such as Sunitinib, a small molecule 
multi-kinase inhibitor that reduces signaling of 
different pathways, such as the vascular endothelial 
growth factor (VEGF) and its receptor (VEGFR-2) by 
down-regulating VEGFR-2 [4–8]. However, resistance 
to anti-angiogenic therapy develops almost 
universally after several months of treatment [9–11]. 
Response to therapy is typically evaluated using 
tumor size measurements and the response 
evaluation criteria in solid tumors (RECIST) [12]. 
However, functional and molecular changes can occur 
before significant change in tumor size. Therefore, it is 
important to accurately track the state of the disease 
and treatment response to better diagnose recurrence 
and tailor therapy. Studies have been conducted using 
dynamic contrast-enhanced imaging and molecular 
imaging (MI) with MRI, PET, and CT, and the results 
indicate that imaging can more accurately track 
disease response to therapy than RECIST [13–16]. 
However, due to the high cost and long imaging 
period of MRI and the radiation dose of PET and CT, 
these modalities are used sparingly and are not ideal 
for serial disease and therapy monitoring. 
Furthermore, lack of portability provides an 
additional challenge, while ultrasound can be used 
with bedside support. To limit exposure and to 
optimally capture the response to treatment, imaging 
is usually limited to once every several weeks or 
months [17]. However, more frequent monitoring is 
desirable for precise tracking of disease state and 
response to therapy.  
In comparison, contrast-enhanced ultrasound 
(CEUS) imaging is an inexpensive and widely 
available technique, which uses contrast agents that 
are safe for patients and have been used for molecular 
and perfusion imaging of disease [18–21]. Therefore, 
CEUS has the potential to be a powerful tool for serial 
monitoring of disease and assessment of early 
response to therapy. Conventional microbubble 
contrast agents are typically composed of a 
perfluorocarbon core and a lipid shell and are able to 
freely traverse the vasculature due to their small size 
(1-5 µm), with clearance by the liver and lungs in a 
matter of minutes. The gas core is compressible and 
provides excellent ultrasound contrast as a result of 
the density mismatch from the surrounding blood 
and tissue. Microbubbles that are interrogated with 
ultrasound emit acoustic signals that can be separated 
from those of normal tissue due to nonlinear bubble 
behavior, and used to produce high-contrast images 
of vasculature [22–24]. CEUS can measure tissue 
characteristics such as blood perfusion [25–27] for 
cardiology [28,29], evaluation and treatment of 
ischemic stroke [30–32], and cancer assessment and 
management [33,34] in animal models of disease. 
Furthermore, by adding targeting ligands such as 
antibodies or peptides, to the shell, ultrasound 
molecular imaging (USMI) can be performed [35]. 
This approach has been evaluated to assess expression 
of different molecular biomarkers associated with 
cardiovascular disease [36–38], inflammatory 
disorders [39,40], and angiogenesis [41–43]. Typically, 
biomarkers expressed on the vascular endothelium 
such as αvβ3 integrin and VEGFR-2 are targeted 
[41,44–47] because available markers are partially 
limited by the confinement of the microbubbles to the 
microvasculature due to their size. In recent years, 
several studies have demonstrated the ability of USMI 
to monitor disease response to anti-angiogenic 
therapy [48–53]. Furthermore, a few studies have 
demonstrated that USMI can predict response to 
therapy in different tumor models; Streeter et al. 
found that USMI is capable of differentiating between 
patient-derived xenografts that respond to aurora-A 
kinase inhibition and non-responders earlier than 
tumor volume as an indicator [54], and Sirsi et al. and 
Wang et al. demonstrated that USMI targeting 
VEGFR-2 can predict tumor response to 
anti-angiogenic therapy before there are measurable 
changes in tumor volume [55,56]. However, to our 
knowledge, all previous work has used group 
statistics to show the effectiveness of USMI to track 
disease progression, and while measuring differences 
in response to therapy between populations can 
provide valuable information for the overall 
treatment of disease, tracking and predicting response 
in individuals is more relevant for clinical translation. 
Here, we demonstrate that USMI can detect response 
to different therapies before tumor volume between 
different treatment groups, as well as for individual 
responses. 
An alternative to anti-VEGF therapy which 
targets VEGF receptors for the treatment of ccRCC is 
the inhibition of the Notch signaling pathway, which 
plays a key role in the proper development of new 
vasculature. Notch signaling promotes vessel growth 





while suppressing excessive sprouting by 
down-regulating VEGF receptor on the endothelial 
cells of the growing stalk [57–59]. Endothelial tip cells 
induce adjacent stalk cells to pattern new vessels 
[58–60]. Binding between Notch ligands such as Dll4 
(Delta-like ligand 4) on tip cells and Notch receptors 
on stalk cells regulates the specialization of 
endothelial cells and limits sprout numbers [58,59]. 
This signaling pathway can be inhibited using gamma 
secretase inhibitors, which inhibit the activation of 
Notch via cleavage induced by ligand binding. 
Therefore, inhibiting Notch signaling yields a 
disproportionate number of tip cells, resulting in 
excessive sprouting and immature vasculature, which 
has been shown to inhibit tumor growth, likely due to 
inefficient perfusion [58,61–64]. Furthermore, the 
increased availability of VEGF receptors might cause 
ccRCC undergoing Notch inhibition to re-sensitize to 
the effects of VEGF receptor targeting. This proposed 
interaction has the potential to be a mechanism for 
overcoming resistance to conventional antiangiogenic 
therapy in ways that may be challenging to monitor 
with conventional imaging.  
In this work, the theranostic ability of ultrasound 
molecular imaging (USMI) to track the response of 
subcutaneous ccRCC tumors to two kinds of therapy 
is explored. Mice were treated with an anti-angiogenic 
VEGF receptor targeting and an inhibitor of Notch 
pathway activation. The results demonstrate that 
USMI can detect differences in treatment response to 
the different modes of vascular inhibition after one 
week of treatment, while tumor size of the treated 
mice does not become significant from that of the 
controls until 3 three weeks after the start of 
treatment. This result implies that USMI can be used 
to detect response to therapy earlier than tumor 
volume measurements alone, providing a low-cost 
bedside tool for routine treatment efficacy assessment 
and personalized medicine. 
Methods 
Microbubble Contrast Agents 
The contrast agents used for the study were 
VEGFR-2 targeted perfluorocarbon microbubbles 
(Visistar VEFGR2, Targeson, San Diego, CA, USA) 
with a mean diameter of 2.23±0.02 μm. Competitive 
binding experiments show that Targeson VEGFR-2 
bubbles produce significantly higher retention in 
tumors than similar control bubbles bearing 
isotype-matched antibodies [41], inactivated 
antibodies [65], or naked microbubbles without 
targeting antibodies [66]. 
Xenograft and Treatment Protocol  
NSG (NOD/scid/gamma) female mice (Mus 
musculus) were injected subcutaneously in the flank 
with 8x109 786-O human renal cell adenocarcinoma 
cells, which were obtained from Dr. William Kim at 
the University of North Carolina [67]. A total of 32 
mice were placed into 4 treatment groups: Notch 
pathway inhibitor GSI (Gamma secretase inhibitor, 
PF-03084014, Pfizer, New York, NY, USA), VEGF 
inhibitor SU (Sunitinib malate, Selleckchem, TX, 
USA), a Switch group (SU to GSI), and Control (100 
µL of saline). The mice were administered a daily dose 
of SU (50 mg/kg) or GSI (90 mg/kg) by oral gavage. 
Treatment started when the tumors reached 200 mm3 
(caliper measurement) and continued for 5 weeks. In 
the case of the Switch group, the mice were treated 
with SU for 3 weeks before switching to GSI.  
Animal Protocol and Contrast Administration 
All imaging was performed using methods 
approved by the UNC Institutional Animal Care and 
Use Committee. An initial pre-treatment scan was 
acquired when the tumors reached 150 mm3, and the 
mice were imaged once per week until the end of 
treatment or until the tumor exceeded 2 cm (long 
axis), at which time they were euthanized in 
accordance with guidelines of the UNC Institutional 
Animal Care and Use Committee requirement. 
During each imaging session, the mice were 
anesthetized with 1.5% isoflurane and body 
temperature (37˚C) was maintained using a heated 
imaging platform. The area of imaging was cleared of 
fur using an electric razor and further depilated using 
a chemical hair remover, and the tissue was coupled 
to the imaging transducer using water-based 
ultrasound gel. A 27G catheter was inserted into the 
tail-vein for the introduction of the Targeson bubbles. 
A bolus of 2x106 microbubbles diluted in 100 µL of 
sterile saline was injected, followed by a 100 µL saline 
flush to clear the catheter and ensure the entire dose 
was delivered. An Accusizer 780 A (Particle Sizing 
Systems, Santa Barbara, CA, USA) was used to size 
the bubbles before every imaging session to ensure a 
precise dose was injected for all experiments. 
Imaging Protocol 
All imaging was performed using an Acuson 
Sequoia 512 (Mountain View, CA, USA) driving a 
15L8 linear array transducer. The imaging protocol 
utilized was a standard protocol for ultrasound 
molecular imaging, as previously described [41], and 
is summarized in Figure 1. A b-mode scan (14 MHz, 
0.63 Mechanical Index) was obtained before the 
introduction of contrast agents for anatomical 
reference using the system’s compounding mode. 
Next, a contrast baseline scan was acquired using 
cadence pulse sequencing (CPS), the imaging system’s 





contrast-specific imaging mode. Contrast imaging 
parameters were: 7 MHz, -7 dB gain, and a 
Mechanical Index of 0.18, and were found to be 
non-destructive in preliminary work. A scan to 
capture the peak contrast enhancement was obtained 
1 min after injection, and the bubbles were allowed to 
circulate for 7 min in order to allow for most of the 
freely-flowing contrast to be cleared from circulation. 
Preliminary studies showed that most of the 
free-flowing contrast was cleared from circulation by 
7 min. Next, a second contrast imaging scan was 
captured, followed by a destructive b-mode scan (14 
MHz, 1.9 Mechanical Index) in which the transducer 
was quickly swept over the tumor volume to remove 
bound bubbles. Lastly, the level of freely-circulating 
contrast was measured with a final contrast imaging 
scan 1 min after the destructive scan. All the imaging 
scans were captured in 3D by sweeping the 
transducer in the elevational direction over the tissue, 
as previously reported [27,68], using a step-size of 400 
μm, and capturing a single contrast frame at each 
step. 
Data Analysis 
The scans were saved as JPEG-compressed 
DICOM files and were taken from the scanner for 
analysis. All analysis was performed using custom 
Matlab scripts (The MathWorks, Inc., Natick, MA, 
USA). The volumetric b-mode scan was used to define 
a 3D region of interest (ROI) encompassing the entire 
tumor volume, and the mean intensity was calculated 
for each of the 3 CPS scans by averaging the intensity 
value of all the pixels inside the ROI. Furthermore, the 
number of pixels inside the ROI was used, in addition 
to the step size, to calculate the volume of the tumors. 
The targeting intensity (TI), a quantitative measure of 
the level of biomarker expression as indicated by the 
retention of targeted contrast in the sample volume, 
was calculated by subtracting the mean intensity of 
the post-destruction CPS scan (Figure 1E) from the 
contrast scan that was taken 7 min after injection 
(Figure 1C). Peak intensity (PI) was calculated by 
subtracting the intensity of the contrast baseline scan 
from that of the 1 min scan. This time point was 
chosen based on preliminary results, which show that 
microbubbles have perfused the entire tissue after 1 
min, and the intensity in this scan is close to the 
maximum enhancement for the tumor model being 
used in this study and treated with the same 
therapies. Aside from finding the peak intensity, the 
PI scan was also used to find regions that did not 
become perfused within 1 min after injection. Based 
on the blood volume, cardiac output, and cardiac 
frequency in mice, microbubbles spread throughout 
the body and circulate the vasculature several times in 
one minute and therefore, anechoic regions that have 
not been perfused by that time do not have patent 
vasculature and should be excluded from analysis. 
Since our intent is to compare biomarker presence 
within the vasculature, inclusion of regions without 
perfusion would bias this result. 
 
 
Figure 1. Summary of imaging protocol. A baseline contrast scan was captured 
prior to the microbubble injection (A). A scan to capture the maximum peak 
intensity was taken 1 min after the introduction of contrast (B). The bubbles 
were allowed to circulate and bind for 7 min, at which time a contrast scan was 
taken (C). Destructive pulses clear the tumor of both bound and freely-flowing 
bubbles (D), and the level of freely-flowing contrast was obtained 1 min after 
destruction to allow bubbles to reperfuse the tissue (E). Note: data was only 
collected at B, C, and E and the solid black line is only an estimate of the intensity 
over time. 
 
Anechoic regions appear dark in the contrast 
images, but due to the nature of speckle, an area that 
is completely perfused will also contain small dark 
regions. Eliminating pixels that have intensities lower 
than a certain threshold would thus eliminate regions 
that are perfused in addition to regions that are 
anechoic. Therefore, the images were blurred using a 
Gaussian filter in order to eliminate small dark 
regions in areas that are full of contrast, in essence 
eliminating the speckle (Figure 2). Next, the regions of 
the image that were inside the analysis ROI and had 
an intensity lower than a predefined threshold were 
removed from the analysis region for the calculation 
of all metrics. The threshold was defined using 
preliminary data, and the same value was used for all 
animals at every time point. Furthermore, the 
different treatments affect functional characteristics of 
the tumor, such as perfusion, so the volume of the 
anechoic areas was used to calculate a “Percent 
Anechoic” (PA) metric to assess the response of the 
disease to the treatment over time. This metric is 
related to the amount of patent vasculature in the 
tumor volume, or lack thereof, due to necrosis or 
other factors. 






Figure 2. Method for obtaining anechoic regions in a peak intensity image (A). The green dots outline the tumor. The image is blurred using a Gaussian filter to 
eliminate dark areas in speckle (B). The regions below a predetermined intensity threshold are selected as anechoic (C). Note: these are single frames in a 3D volume, 
so the process will be performed for each slice in the volume. 
 
 
Figure 3. Example of individual response to the treatment. The solid lines represent either the TI (dark gray), PA (light gray), and the volume (black) for a single 
animal, while the dashed lines represent the threshold for each metric calculated using the Control group data. Each metric was determined to show resistance if the 
individual value (solid) was lower, for the TI and Volume, or higher, for the PA, than its threshold (dashed). The data for each metric were normalized to the 
pretreatment value, and by an additional factor in order to display the curves in the same scale. 
 
CD31 Immunohistochemistry 
CD31 immunohistochemistry was performed to 
serve as a gold standard for comparison against 
imaging results. Tumors were harvested after the last 
imaging time point or earlier if the size limit was 
exceeded, or due to poor health. 
Immunohistochemistry was performed on 
paraffin-embedded tumor sections on a Leica Bond 
Max autostainer using anti-CD31 from Novocastra 
(cat # NCL-CD31-1A10). Following heat-induced 
epitope retrieval in EDTA for 20 min, the antibody 
was incubated on the tissue for 1 h at a dilution of 
1:100 then visualized with diaminobenzidine (DAB). 
Thirty stained sections from each treatment group 
were captured by an Olympus DP 72 or an Infinity2 
camera at 200x, and the percentage of positively 
stained area (SA) was determined using NIH ImageJ. 
A separate cohort of animals was treated with SU and 
their tumors were harvested after 3 weeks of 
treatment to obtain a pre-switch measurement of 
patent vasculature. 
Statistical Analysis 
Kruskal-Wallis analysis was performed for each 
time point and metric (TI, PI, PA, volume) in order to 
determine if there was a significant difference 
between any of the groups, and a Tukey range test 
was used to find significance between each of the 
groups. Statistical analysis was performed on all mice 
available at each time point, regardless of whether the 
animal survived through the end of the study. 
ANOVA analysis was used to find any significance 
between the groups for histology instead of the 
Kruskal-Wallis method. 
Individual Responses 
The response of individual mice to the 
treatments was compared to the group TI, PA, and 
volume of the Control mice (Figure 3). A threshold 
was found for each of the metrics so that any values 
above (or below) the threshold for individual mice at 
the different time points represented response to the 
treatment. For example, the individual volume (solid 
black line) in Figure 3 becomes smaller than the 
volume threshold (dashed black line) 3 weeks after 





the start of treatment, so it can be said that response 
was detected in the tumor volume at this time. The 
threshold value at each time point was calculated as 
the first quadrant of the grouped Control data at each 
time point for the TI and volume and the third 
quadrant for the PA. Finally, the percentage of mice in 
the SU and Switch groups that showed response to 
the therapy using each metric was calculated for the 
first 3 weeks of treatment.  
Results 
Example US images, taken 7 min after injection 
(Figure 1C), of a single mouse for each group are 
shown in Figure 4. The Control and GSI mice looked 
very similar throughout the study, but the effect of SU 
was apparent; for both the SU and Switch mice, the 
ultrasound intensity decreased after treatment, and 
the tumors became increasingly anechoic, suggesting 
necrosis. However, the size of the anechoic region 
decreased and the intensity increased immediately 
after the switch to GSI for the Switch group. Many 
mice in the GSI and Switch groups were euthanized 
before the fifth imaging session after treatment due to 
tumor size, and some of the SU-treated mice were 
euthanized prior to the end of the experiment due to 
morbidity. This left 1, 5, 3, and 5 mice in the GSI, SU, 
Switch, and Control groups, respectively, for the final 
time point. The data for the remaining mouse in the 
GSI group is not shown. The same mice were imaged 
for the duration of the study, and each group 
contained at least 6 mice at each time point. Results 
were not obtained for all the mice at each of the time 
points due to a technical problem saving the data on 
the Sequoia or due to lack of patent tail vein access on 
some animals late in the study. A detailed account of 
the results, statistical analysis, and the number of mice 
in each group and each time point can be found in 
Tables 1, 2, and 3.  
Targeting Intensity 
A significant difference in targeting intensity 
(TI), a measure of VEGFR-2 expression, can be seen 2 
weeks following the start of treatment (Figure 5). TI 
for SU became, and remained, significantly lower 
than that of the Control group after the first week (p < 
0.05 for all time points after the first week of 
treatment), while the TI of the GSI group remained 
non-significant from the Control group for the 
duration of the experiment. TI for the Switch group 
mimicked that of the SU group for the first 3 weeks 
after the start of treatment, but it increased after the 
switch to GSI and became non-significant from the 
GSI and Control groups 1 week after the switch. It is 
important to note that when the SU and Switch 
groups are combined, the TI was significant (p < 0.05) 
from that of the Control group 1 week after the start of 
treatment. Additionally, a subset of the SU and Switch 
groups was imaged 2 days after the start of treatment 
and there was a significant difference (p < 0.05) in the 
TI between this early time point and the baseline scan. 
USMI was able to closely track changes of VEGFR-2 
expression as the result of the two types of therapy. 
 
 
Figure 4. Example US images of different treatment groups taken 7 min after injection (Figure. 1C). GSI and Control groups remained similar throughout the study. 
TI for the SU and Switch groups decreased after the start of treatment, and the tumors became more anechoic. PA and TI increased for the Switch group after the 
treatment was changed to GSI, indicated by the red arrows. The strong reflections in the images are artifacts and were excluded from the analysis. 





Table 1. Medians and Interquartile Ranges (IQR) for Targeting Intensity (TI), Peak Intensity (PI), Percent Anechoic (PA), and volume for 
each imaging week. 
 Imaging Week 
-1 1 2 3 4 5 
Med IQR Med IQR Med IQR Med IQR Med IQR Med IQR 
TI GSI 19.9 5.0 20.6 2.8 19.2 3.0 18.6 8.7 17.2 3.1 17.5 0.0 
SU 18.0 1.9 11.2 3.5 5.2 3.7 6.1 1.7 9.9 1.9 12.4 1.8 
Switch 18.2 4.2 10.0 3.3 8.4 3.1 7.0 2.7 17.5 1.6 19.2 0.1 
Control 22.7 5.3 17.2 2.0 17.8 5.6 19.9 3.3 18.0 2.4 15.1 1.9 
 
PI GSI 29.5 7.3 31.5 6.5 28.3 2.9 30.4 7.0 27.6 3.9 27.2 0.0 
SU 28.2 2.4 27.1 2.9 24.3 2.1 24.0 1.8 26.1 1.3 26.6 0.3 
Switch 31.8 4.9 25.6 2.8 24.4 2.5 24.2 2.8 27.6 2.7 30.1 1.4 
Control 32.9 4.7 26.2 6.0 28.4 5.3 30.4 3.3 28.3 6.0 27.2 1.2 
 
PA GSI 8.3 6.4 8.9 9.3 13.0 9.0 14.6 19.3 27.8 21.5 26.6 0.0 
SU 7.9 4.1 32.7 12.8 59.9 12.0 66.9 4.2 57.2 6.4 49.7 3.5 
Switch 5.3 5.6 32.5 20.3 60.3 18.8 66.0 18.8 37.2 6.3 31.2 8.2 




GSI 241.9 94.5 483.4 133.6 719.8 283.0 951.1 249.3 1166.2 275.7 1391.6 0.0 
SU 191.1 76.8 446.8 170.6 421.4 175.1 416.9 238.4 490.8 160.9 562.6 82.2 
Switch 221.0 69.3 361.5 155.2 495.1 109.6 543.9 216.0 966.5 164.9 1040.8 218.8 
Control 167.5 52.1 381.6 107.1 589.1 240.6 720.9 137.9 861.9 228.6 1248.5 320.2 
 
Table 2. P-values between all treatment groups. Targeting Intensity (TI), Peak Intensity (PI), Percent Anechoic (PA), volume. 
 Imaging Week 
-1 1 2 3 4 5 
TI GSI-Control 0.935 0.887 0.993 0.804 0.915  
SU-Control 0.333 0.079 0.002 < 0.001 0.006 0.148 
Switch-Control 0.721 0.041 0.031 0.004 1.000 0.302 
SU-GSI 0.663 0.005 < 0.001 0.015 0.050  
Switch-GSI 0.968 0.002 0.013 0.048 0.933  
Switch-SU 0.887 0.997 0.829 0.961 0.007 0.006 
 
PI GSI-Control 0.998 0.136 1.000 0.999 0.997  
SU-Control 0.603 0.988 0.093 0.032 0.719 0.542 
Switch-Control 0.960 0.986 0.200 0.055 0.995 0.280 
SU-GSI 0.632 0.226 0.093 0.017 0.843  
Switch-GSI 0.984 0.035 0.200 0.030 1.000  
Switch-SU 0.817 0.895 0.983 0.992 0.838 0.039 
 
PA GSI-Control 0.997 0.542 0.979 1.000 1.000  
SU-Control 0.984 0.424 0.022 0.008 0.002 0.177 
Switch-Control 0.988 0.215 0.008 0.007 0.338 0.978 
SU-GSI 0.920 0.013 0.006 0.004 0.003  
Switch-GSI 0.999 0.002 0.002 0.004 0.362  
Switch-SU 0.860 0.982 0.986 1.000 0.171 0.185 
 
Volume GSI-Control 0.188 0.031 0.340 0.309 0.107  
SU-Control 0.951 0.694 0.535 0.066 0.069 0.008 
Switch-Control 0.307 0.800 0.939 0.399 0.963 0.676 
SU-GSI 0.458 0.368 0.012 < 0.001 < 0.001  
Switch-GSI 99.338 0.227 0.098 0.004 0.276  
Switch-SU 0.627 0.996 0.857 0.763 0.019 0.184 
 
Peak Intensity 
The peak intensity signal (PI), captured 1 min 
after the injection of contrast, was reduced for the SU 
and Switch groups in comparison to the Control and 
GSI groups, but the results were only statistically 
significant (p < 0.05) 3 weeks after the start of 
treatment (Figure 6). The Switch group PI became 
significant from that of the SU group 5 weeks after the 
start of treatment. The PI did not provide any 
significant trends or differences between groups that 
indicate the ability to track response to therapy. 
Percent Anechoic 
The groups that were treated with SU showed 
increased percentages of anechoic regions (PA) as the 
treatment progressed (Figure 7). The SU and Switch 
group became significantly higher (p < 0.05) than the 





Control 2 weeks after the start of treatment and 1 
week after the start of treatment compared to the GSI 
group. The SU group remained significantly higher 
than the Control and GSI groups for the remainder of 
the study, except on the last time point, while the 
Switch group decreased after the switch to GSI and 
became non-significant from the Control and GSI 
groups and significant from the SU group (p < 0.05) 
the week following the switch. The PA for the GSI and 
Control groups steadily rose throughout the study but 
remained smaller and non-significant from the SU 
group. PA provided a useful measure of how the 
therapy was affecting the amount of patent 
microvasculature in the tumor throughout the 
treatment, and the results agreed with the reported 
effect of the drugs.  
 
Table 3. Number of animals in each treatment group at each time 
point. 
 Imaging Week 
-1 1 2 3 4 5 
GSI 6 8 7 8 7 1 
SU 6 7 8 7 6 5 
Switch 7 8 8 8 8 3 




Figure 5. TI for the GSI and Control groups remained high throughout the study, while it remained low for the SU and Switch groups. However, TI increased in the 
Switch group after the change to GSI. Asterisks represent significance (p < 0.05), and the x axis represents the imaging week, where imaging week ‘-1’ is the week 
before the start of the treatment.  
 
 
Figure 6. Peak intensity was typically lower for the groups treated with SU but this relationship was only significant 3 weeks after the start of treatment. PI increased 
for the Switch group once the mice were treated with GSI and became significant from SU 2 weeks after the switch. 






Figure 7. Percent Anechoic metric. Groups treated with SU displayed increased percentages of anechoic regions. The Switch group returned to levels similar to 
those of the Control group after the switch to GSI. The size of anechoic regions remained low for the GSI and Control groups. 
 
 
Figure 8. A reduction in tumor growth was displayed by the groups treated with SU, while an enhancement in tumor growth was observed for the GSI treatment 
group but was only significant at the 1-week point. The volume for the SU group became significant from GSI 2 weeks after the start of treatment, and after 5 weeks 
from the controls. The p-value between the SU and Control groups on week 4 was 0.069.  
 
Tumor Volume 
GSI enhanced tumor growth (p < 0.05) 1 week 
after the start of treatment and was significantly 
higher than the Control throughout the study except 2 
weeks after the start of treatment (Figure 8). The 
groups treated with SU displayed reduced tumor 
growth throughout the study. The SU group became 
statistically lower (p < 0.05) than the GSI and Control 
groups 2 and 5 weeks after the start of treatment, 
respectively. The volume for the Switch group was 
similar to that of SU initally, but the change to GSI 
produced an enhancement in the tumor growth, as 
was the case with the GSI group, so that the tumor 
volume grew to be significant from the SU group (p < 
0.05) one week after the switch. The change in volume 
eventually demonstrated a response to SU, but it was 
much later than USMI results. 
CD31 Immunohistochemistry 
Immunohistochemistry was performed to 
examine the amount of patent vasculature, and, 
consequently, the amount of vasculature expressing 
VEGFR-2 in the tissues of treated xenograft tumors 
collected at the end of the study. Representative 
images of the different groups are shown in Figure 9. 





The stained area (SA) was calculated, and the results 
show that the SU group had a value that is 
significantly lower, while the Switch group was 
significantly higher, from all other groups. The GSI 
and Control groups were not significantly different in 
this model. Furthermore, the Pre-Switch group was 
significant from the Switch group. Overall, these 
findings corresponded closely with the in vivo 
assessments using ultrasound imaging. 
Individual Responses 
Figure 10a-b shows examples of individual 
responses in the SU group for the TI, PA, and volume 
metrics, and Figure 10c-d gives examples of the 
Switch group. Analysis of individual responses shows 
that there were cases in both the SU and Switch 
groups in which the tumor volume showed response 
to the treatment at the same time as the other metrics. 
In both b and d, the individual volume value is 
smaller than the volume threshold 1 week after the 
start of treatment. However, the percentage of mice 
that showed response for each of the metrics over the 
first 3 weeks of treatment was calculated (Table 4), 
and the TI, PA, and volume detected response in 
92.3%, 76.9%, and 40.0%, respectively, of the mice 
after the first week of treatment. These percentages 
increased to 100%, 92.3%, and 56.25% for the second 
week and to 100%, 100%, and 93% for the third week. 
Interestingly, volume was very sensitive to the change 
of treatment in the Switch group, and all tumors grew 
at a faster rate than that of the SU group after week 3 
(Figure 10c-d). However, the change in TI and PA 
after the switch was much more abrupt, especially for 
TI, where 85% of individual values became larger 
than the threshold after the switch. The results 
demonstrate TI and PA were able to detect response 
to therapy earlier than tumor volume in individual 
cases. 
 
Table 4. Percentage of cases where response to therapy was 
detected using Targeting Intensity (TI), Percent Anechoic (PA), 
and tumor volume over the first 3 weeks of treatment. 
 Imaging Week 
1 2 3 
TI 92.3 100 100 
PA 76.9 92.3 100 
Volume 40 62.5 100 
 
Discussion 
Resistance to therapy is the major limitation of 
disease control in most cancer types. Thus, it is 
important to track disease response to adjust 
treatment for enhanced efficacy. CEUS is an attractive 
tool for this purpose because it is inexpensive, safe, 
and widely available. Attaching targeting ligands to 
microbubbles allows for molecular imaging of 
biomarkers expressed in different diseases. Here, it is 
shown that the response of ccRCC tumors to VEGFR-2 
antiangiogenic and Notch inhibition therapeutics in 
mice can be accurately tracked throughout the course 
of therapy using USMI of VEGFR-2, and the imaging 
results agree with histological data. Furthermore, we 
show that USMI can detect statistically significant 
molecular and functional changes weeks before 
measureable differences in tumor volume between the 
treatment groups and the Control group, which 
indicates that USMI can be a powerful theranostic 
tool. This is consistent with findings from previous 
work [48–53], but we have also shown here that USMI 
can detect response to therapy in individual cases 
before changes are detectable in tumor volume. 
 
 
Figure 9. Representative images of CD31 immunohistochemistry (top). The dark brown stains represent expression of CD31 in endothelial cells. SA results from CD31 staining 
(bottom). The plot on the left displays the SA of the different treatment groups, while the plot on the right only shows the SU, Switch, and the Pre-Switch cohorts. The SU group 
has significantly lower values from the other groups, while the Switch group showed significantly higher levels of patent vasculature. The Pre-Switch cohort is significant from the 
Switch group. 






Figure 10. Examples of individual responses of SU (rows a and b) and Switch (rows c and d). The solid lines represent the individual values of TI (dark gray), PA (light 
gray), and volume (black) at each time point, while the dashed lines represent the group threshold for each metric, which was obtained from the Control data.  
 
Antiangiogenic drugs, such as SU, enzymatically 
inhibit and down-regulate VEGFR-2 to inhibit 
angiogenesis [7,8]. We were able to observe changes 
in TI corresponding to changes in expression of 
VEGFR-2. The results show that the anti-VEGF 
therapy was effective at arresting development of new 
vasculature, which may have led to anechoic areas, 
and more importantly, that CEUS can track the tumor 
response to the treatment more accurately than 
volume measurements. Additionally, the results 
showed that a significant difference in TI can be found 
only 2 days after the start of treatment. This is 
consistent with recent findings indicating that a 
change in VEGFR-2 expression 24 h after treatment 
can be detected with USMI using microbubbles 
targeted to VEGRF-2 before there are detectable 
changes in tumor growth [48]. Furthermore, the effect 
of SU can easily be seen in the tumors as an increase in 
anechoic areas and quantified in the PA metric, which 
provides another example of the ability of CEUS to 
detect tumor response to treatment faster and more 
accurately than tumor growth (Figure 8). Moreover, 
PA calculations can be accomplished with 
non-targeted contrast, which could facilitate 
translation into the clinic since non-targeted contrast 
agents, such as Definity (Lantheus Medical Imaging, 
N. Billerica, MA, USA), are already FDA approved for 
certain applications. 
TI and PA results showed that CEUS can detect 
response of populations to therapy, which can be 
important for designing new treatment regimens for 
combating cancer. However, detecting response in 
individuals is more significant for clinical translation 
since physicians use individual patient information to 





tailor the treatment. Here, we show that CEUS was 
able to detect the individual response to therapy of 
most of the mice in the SU and Switch groups by the 
second week of treatment, while the chance of 
detecting response with the tumor volume by that 
time was slightly higher than a coin toss. Therefore, 
CEUS has great potential as a personalized 
theranostic tool. 
Taken together, these results demonstrate that 
CEUS has the potential to be a valuable clinical tool 
for assessing response to treatment without having to 
biopsy the tissue or wait for delayed changes in tumor 
size and may allow doctors to tailor treatment to 
individuals for better efficacy. Furthermore, early 
identification of ineffective treatments may reduce 
side effects. 
The PI did not significantly vary between 
treatment groups, which is surprising given that the 
GSI and Control groups seemed to have better 
perfusion and smaller anechoic areas (Figure 7). A 
possible explanation of why PI remained similar 
among the groups is that there is significant bubble 
binding by 1 min and therefore, the intensity might be 
a result of the perfusion of the tissue in addition to 
VEGFR-2 expression. Thus, PI might not be suitable 
for the assessment of disease progression. A better 
technique might be to track the intensity for the first 
few minutes after injection in order to find the true 
peak intensity, as is done by Wang et al. [48], which 
showed that peak intensity can measure changes in 
response to therapy. 
The results of the staining demonstrate that 
USMI of VEGFR-2 demonstrates real physiological 
characteristics of disease. As expected, levels of patent 
vasculature in the SU group were the lowest among 
all of the groups, while those of GSI and Control were 
about the same (Figure 9). Furthermore, the Switch 
group had significantly higher SA than all other 
groups, most likely caused by the switch to GSI. 
Additionally, the Pre-Switch SA was significantly 
lower than the Switch group, confirming that the 
increase in patent vasculature in the Switch group 
was caused by the change in treatment. Staining for 
VEGFR-2 was also performed, but the results showed 
expression in regions where patent vasculature was 
not present. Most likely, this is a result of 
extravascular VEGFR-2 expression or endothelial 
receptors of non-patent vessels. Since the contrast 
agents used in this study can only bind to 
intravascular VEGFR-2 receptors, VEGFR-2 staining 
results were not included. Nevertheless, we believe 
that USMI can be a valuable tool for disease 
monitoring, since it provides information about 
molecular biomarkers of disease that can be used to 
closely track disease state and response to therapy 
without the need for multiple biopsies or exposure to 
ionizing radiation. 
The Notch signaling pathway regulates proper 
development of new vasculature, and it has been 
reported that inhibition leads to excessive sprouting, 
immature vessels, and a reduction in tumor growth 
[61–63]. Notch inhibition promotes expression of 
VEGFR-2, so it is not surprising that the TI of the GSI 
group remained high throughout the experiment 
(Figure 5). Moreover, it is not surprising that the 
Control and GSI groups had similar levels of TI, since 
ccRCC is characterized by increased levels of 
angiogenesis and upregulation of angiogenic growth 
factors. Previous work suggests that the excessive 
sprouting resulting from Notch inhibition leads to 
inefficient perfusion and a reduction in tumor growth 
[61–64]; however, the results of treatment with this 
drug as a single agent in a ccRCC xenograft model 
demonstrate efficient vasculature in the GSI group 
with PA and PI values similar to the controls and an 
enhancement in tumor growth. This somewhat 
surprising result, however, must be considered in 
context. In the study reporting on GSI Compound X 
causing regression in a renal cancer model, Kalen et 
al. [69] were utilizing the mouse RENCA model. This 
model system differs from ours in important ways. 
First, while this is a spontaneously arising kidney 
tumor from a Balb/C mouse, it lacks the common 
feature of human renal cell carcinoma, which is 
inactivation of the von Hippel-Lindau (VHL) gene. 
VHL loss causes a high level of tumor 
microvascularity and upregulation of glycolysis, 
driving a unique dependency on oxygen and nutrient 
delivery. It is this dependency that renders VHL 
mutant renal cell carcinoma sensitive to the wide 
variety of anti-VEGF pathway agents currently in 
clinical use. However, this dependency may make the 
extra sprouting produced in response to GSI 
treatment an advantage to the specific physiology of 
this tumor type. Our model has a well-characterized 
VHL mutation and is known to demonstrate 
customary features of human clear cell renal cell 
carcinoma. The interaction between VEGF pathway 
targeted therapy and the vascular effects of GSI, 
however, highlights an intriguing alternate set of 
targeting strategies to alter vascular properties in 
tumors, the combination of which may be effective in 
renal cell carcinoma and potentially in a wider array 
of cancer settings. As discussed above, finding the PI 
may not be the best technique for approximating 
perfusion measurements, so further work is required 
to assess changes in perfusion efficiency as a result of 
Notch inhibition.  
When the tumors in the Switch group were 
treated with GSI, the treatment appeared to normalize 





features of the vasculature, promoting angiogenesis 
so that the PA was reduced to levels similar to those 
of the controls. Higher TI suggests greater expression 
of VEGFR-2 (Figure 5). This reversal in the state of the 
vasculature is only detectable by using CEUS, since 
the tumor volume of the Switch group remains 
non-significant from the Control group. However, the 
volume of the Switch group did become significant 
from that of the SU group 1 week after the change in 
treatment to GSI. 
Normalization of tumor vasculature has been 
shown to enhance therapeutic effect in different types 
of cancer [70–72]. Tumor vasculature is leaky, which 
produces increased interstitial pressure, and in turn 
inhibits delivery of therapy into the tissue [73, 74]. By 
normalizing the vasculature and making it less 
permeable, the interstitial pressure can be reduced, 
allowing for drugs to extravasate in larger 
concentrations for better efficacy [73–75]. We have 
shown that GSI produced normalization in the 
vasculature in ccRCC tumors that were first treated 
with SU. Additionally, it is possible that by 
renormalizing the vasculature of tumors that stop 
responding to antiangiogenic therapy, resistance can 
be overcome. Moreover, we show here that 
ultrasound can be used to track the progression of the 
disease and even though we did not conclusively 
detect the emergence of resistance to SU in the time 
frame of the study, CEUS can be used to monitor the 
disease and make the switch to GSI when the tumors 
start showing signs of resistance.  
The mice were imaged on set days of the week, 
when the tumor reached 200 mm3 (caliper 
measurement). Since not all of the tumors reached the 
size threshold at the same time, some mice were 
treated for different durations before their first 
imaging session after the start of treatment. Therefore, 
the effect measured by the different metrics on week 1 
(the week after the start of treatment) might have been 
reduced and may be more drastic than the data show. 
Furthermore, the small number of mice in each group 
may have affected at which time point response was 
detected with the different metrics. For example, the 
volume of the SU and Control groups does not 
become significant until 5 weeks after treatment, but 
the p-values for week 3 and 4 are 0.066 and 0.069, 
respectively. Larger sample sizes would be required 
to validate this effect. An additional limitation of the 
study was that all analysis was performed on log 
compressed data, and while data compression did not 
allow calculation of absolute differences in intensity 
between the different treatment groups for PI and TI, 
relative differences are still valid, so the overall trends 
and results hold. 
Since statistical analysis was performed on all 
mice at each time point, even if they did not survive 
the entire study, the results might be biased and 
indicate a better treatment efficacy for the SU group; 
presumably, if the health of the mouse was poor, the 
tumor could progress more aggressively than in a 
healthy mouse. However, most of the morbidity was 
due to tumor size limitations, so we do not expect that 
the overall results of the study would be significantly 
changed if statistical analysis were only performed on 
the animals that survived the entire study. 
While the different treatments slowed the tumor 
growth, no regression or stagnation was observed in 
this study. In the case of SU, the dose was chosen 
based on previous work [64, 65], and absence of 
regression is likely due to the early emergence of 
resistance. The chosen dose of GSI, 90 mg/kg, was 
shown to be effective against a breast cancer model 
[66], but it was not optimized for this work, so it is 
possible that the mice were under-dosed. However, 
we observed vascular effects that were histologically 
consistent with the enhanced sprouting expected with 
Notch inhibition. In addition, mice suffered from 
weight loss in pilot studies where a dose of 150 
mg/kg was used.  
Since most of the mice were sacrificed because 
their tumors grew beyond the size limit, it is difficult 
to evaluate survival outcome. Therefore, even though 
USMI can be used to track disease progression, more 
work is required to assess the ability of this technique 
to predict eventual survival outcomes. 
Conclusions 
In this study, mice bearing ccRCC tumors were 
treated with VEGFR-2 antiangiogenic and Notch 
inhibition therapy. It was observed that USMI can be 
used to monitor the disease progression and its 
response to the different therapies more accurately 
than using the conventional methods of tracking 
tumor volume. Furthermore, we explored the effects 
of Notch inhibition as an alternate strategy of vascular 
disruption and showed that this type of treatment 
maintained or enhanced tumor growth in the context 
of this xenograft model by decreasing anechoic areas 
and promoting angiogenesis. Other work in recent 
years has shown that USMI can track response to 
antiangiogenic therapy [48–53] and predict whether 
tumors will respond to different treatments [54–56]; 
however, this is the first study to show that USMI can 
differentiate and track response to alternate strategies 
of vascularity-altering therapies and detect the tissue 
response of individual animals using USMI earlier 
than tracking changes in tumor volume. Ultrasound is 
an inexpensive, safe, and widely available technology 
that when used in conjunction with microbubble 
contrast agents, can be a valuable theranostic tool 





because it has the capability to assess response to 
therapy in cancer and monitor disease progression 
which might allow doctors to modify patient 
treatment for enhanced therapeutic effect. 
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